Eton Pharmaceuticals, Inc.

ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.

Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.

Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million or 49% of revenue Raised 2026 revenue guidance to more than $175 million, up from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, up from prior guidance of more …

Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% increase with placebo Company plans additional study arms in 2027 evaluating faster-release formulations to seek to improve copper absorption inhibition while preserving favorable safety profile DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” o…

DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026 as follows:

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approval Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027 Company to host investor call on November 4, 2026, …

Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.

DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 and the active ingredient in INCRELEX, which Eton markets in the United States. The Company ha…

DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.

Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 45,993 shares of the company's stock, valued at approximately $2,368,000. Robeco Institutional Asset Management B.V. owned about 0.16% of

DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that they have entered into an exclusive l…

Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Earnings and Valuation This table compares Cronos

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO® (miltefosine) capsules.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target

Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company's stock, valued at approximately $476,000. Other large investors have also

BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company's stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the

Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company's stock after purchasing an additional 39,571 shares